Key Points
- BridgeBio director Andrea Ellis sold 64,921 shares at an average price of $64.87 for a total of $4,211,425.27, leaving her with 18,589 shares — a 77.74% reduction in her ownership (transaction filed with the SEC).
- Quarterly results mixed: BridgeBio reported (‑$1.00) EPS, missing the (‑$0.75) estimate, while revenue of $154.18 million beat expectations and rose 2,521.2% year‑over‑year.
- Analysts remain mostly bullish: 22 Buy vs. 1 Sell with a consensus "Moderate Buy" and $82.50 price target; market cap is about $12.7 billion and the stock trades in the mid‑$60s.
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Andrea Ellis sold 64,921 shares of the company's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $64.87, for a total transaction of $4,211,425.27. Following the completion of the sale, the director directly owned 18,589 shares of the company's stock, valued at approximately $1,205,868.43. This trade represents a 77.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
BridgeBio Pharma Stock Performance
NASDAQ BBIO opened at $65.36 on Friday. BridgeBio Pharma, Inc. has a one year low of $28.33 and a one year high of $84.94. The company has a market capitalization of $12.67 billion, a price-to-earnings ratio of -17.29 and a beta of 1.13. The company's 50-day simple moving average is $73.64 and its two-hundred day simple moving average is $65.22.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The firm had revenue of $154.18 million for the quarter, compared to analysts' expectations of $150.71 million. During the same period in the previous year, the firm earned ($1.40) earnings per share. The business's revenue for the quarter was up 2521.2% on a year-over-year basis. Equities analysts expect that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on the company. Barclays began coverage on BridgeBio Pharma in a research report on Wednesday, January 28th. They set an "overweight" rating on the stock. Sanford C. Bernstein initiated coverage on BridgeBio Pharma in a research note on Thursday, December 11th. They set an "outperform" rating and a $94.00 price objective for the company. Raymond James Financial set a $89.00 price objective on BridgeBio Pharma and gave the company an "outperform" rating in a research report on Thursday, February 12th. JPMorgan Chase & Co. lifted their target price on BridgeBio Pharma from $76.00 to $77.00 and gave the company an "overweight" rating in a research note on Friday, November 7th. Finally, Truist Financial increased their price target on shares of BridgeBio Pharma from $86.00 to $95.00 and gave the company a "buy" rating in a research report on Wednesday, February 25th. Twenty-two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $82.50.
Get Our Latest Report on BridgeBio Pharma
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in BBIO. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in BridgeBio Pharma during the 2nd quarter valued at about $25,000. Aster Capital Management DIFC Ltd acquired a new stake in BridgeBio Pharma in the third quarter worth about $31,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of BridgeBio Pharma during the third quarter worth about $34,000. Jones Financial Companies Lllp purchased a new stake in shares of BridgeBio Pharma during the first quarter worth about $35,000. Finally, First Horizon Corp acquired a new position in shares of BridgeBio Pharma during the third quarter valued at about $36,000. 99.85% of the stock is currently owned by hedge funds and other institutional investors.
BridgeBio Pharma Company Profile
(
Get Free Report)
BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.
BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
